Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Cardiovascular Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RAMP2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAMP2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View RAMP2 Products |
| Gene Delivery | RAMP2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and GPCR co-transfection. |
View RAMP2 Products |
| Benchmark Ab | Anti-RAMP2 Benchmark Antibody Recombinant positive control derived from clinical-stage leads. |
View RAMP2 Products |
| Validator | RAMP2 siRNA Set For knockdown verification in target-specific assays. |
View RAMP2 Products |
| Related Target A | CALCRL The obligate GPCR partner that heterodimerizes with RAMP2 to form the active Adrenomedullin 1 (AM1) receptor. |
View CALCRL Products |
| Related Target B | RAMP1 Homologous receptor activity-modifying protein used for counter-screening to ensure RAMP2 therapeutic selectivity. |
View RAMP1 Products |
| Related Target C | RAMP3 Homologous family member crucial for off-target profiling and specificity verification. |
View RAMP3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Functional GPCR Complex Reconstitution | Lentivirus systems for stable co-expression of RAMP2 and CALCRL to preserve native GPCR-RAMP conformation. |
| Subfamily Off-Target Screening | High-purity RAMP1 and RAMP3 recombinant proteins available for stringent selectivity profiling. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included for assay validation. |
| False Positives | Validated siRNA sets included for target knockdown and specificity confirmation. |
Live RAMP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RAMP2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and small molecule modulators. As first-generation therapies targeting the adrenomedullin pathway reach the clinic, the next wave of R&D is targeting RAMP2 selectively to modulate vascular permeability, tumor angiogenesis, and cardiovascular hemodynamics without inducing systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Oncology-focused Biopharma | Solid Tumors, Angiogenesis | Blocking Assay (Need high-purity RAMP2 ECD-Fc to block ligand binding) |
| Bispecific Antibodies | Immunotherapy Developers | Vascular Disorders, Oncology | Heterodimer Validation (Need cross-reactive CALCRL/RAMP2 complexes) |
| Small Molecule Modulators | Cardiovascular Therapeutics | Heart Failure, Preeclampsia | Functional GPCR Screening (Need RAMP2/CALCRL co-expressing stable cell lines via Lentivirus) |